A nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancer

Wang,Hao; Meng,Ai‑Min; Li,Sheng‑Hua; Zhou,Xiao‑Liang

doi:10.3892/mmr.2017.6677

A nanobody targeting carcinoembryonic antigen as a promising molecular probe for non-small cell lung cancer

Authors:
- Hao Wang
- Ai‑Min Meng
- Sheng‑Hua Li
- Xiao‑Liang Zhou
View Affiliations

Affiliations: Tianjin Key Laboratory of Radiation Medicine and Molecular Nuclear Medicine, Institute of Radiation Medicine, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin 300192, P.R. China, Tianjin Shengfa NabioTech Co., Ltd., Tianjin 300457, P.R. China
Published online on: June 1, 2017 https://doi.org/10.3892/mmr.2017.6677
Pages: 625-630
Copyright: © Wang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Carcinoembryonic antigen (CEA) is a biomarker and therapy target for non‑small cell lung cancer (NSCLC), which is the most common type of lung cancer. Nanobodies with high target specificity are promising candidates to function as anti‑CEA probes. In the present study, the targeting effects of an anti‑CEA nanobody obtained from phage display were investigated using technetium‑99 m (99mTc) and fluorescence labeling. In vitro binding and immunofluorescent staining assays, as well as in vivo blood clearance and biodistribution assays were performed. High specificity and affinity of the nanobody for CEA‑positive H460 cells was observed in vitro. The pharmacokinetics assay of the 99mTc‑nanobody in Wistar rats demonstrated that the nanobody had appropriate T1/2α and T1/2β, which were 20.2 and 143.5 min, respectively. The biodistribution assay using H460 xenograft‑bearing nude mice demonstrated a high ratio of signal in tumor compared with background, which confirmed that the nanobody may be useful as a molecular probe for CEA‑positive cancer, particularly in NSCLC.

View Figures

View References

1	Gold P and Freedman SO: Demonstration of tumor-specific antigens in human colonic carcinomata by immunological tolerance and absorption techniques. J Exp Med. 121:439–462. 1965. View Article : Google Scholar : PubMed/NCBI
2	Krupey J, Gold P and Freedman SO: Purification and characterization of carcinoembryonic antigens of the human digestive system. Nature. 215:67–68. 1967. View Article : Google Scholar : PubMed/NCBI
3	Wahl RL, Philpott G and Parker CW: Monoclonal antibody radioimmunodetection of human-derived colon cancer. Invest Radiol. 18:58–62. 1983. View Article : Google Scholar : PubMed/NCBI
4	Jeon BG, Shin R, Chung JK, Jung IM and Heo SC: Individualized cutoff value of the preoperative carcinoembryonic antigen level is necessary for optimal use as a prognostic marker. Ann Coloproctol. 29:106–114. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yang KL, Yang SH, Liang WY, Kuo YJ, Lin JK, Lin TC, Chen WS, Jiang JK, Wang HS, Chang SC, et al: Carcinoembryonic antigen (CEA) level, CEA ratio, and treatment outcome of rectal cancer patients receiving pre-operative chemoradiation and surgery. Radiat Oncol. 8:432013. View Article : Google Scholar : PubMed/NCBI
6	Eftekhar E and Naghibalhossaini F: Carcinoembryonic antigen expression level as a predictive factor for response to 5-fluorouracil in colorectal cancer. Mol Biol Rep. 41:459–466. 2014. View Article : Google Scholar : PubMed/NCBI
7	Das A, Barik S, Banerjee S, Bose A, Sarkar K, Biswas J, Baral R and Pal S: A monoclonal antibody against neem leaf glycoprotein recognizes carcinoembryonic antigen (CEA) and restricts CEA expressing tumor growth. J Immunother. 37:394–406. 2014. View Article : Google Scholar : PubMed/NCBI
8	Conaghan P, Ashraf S, Tytherleigh M, Wilding J, Tchilian E, Bicknell D, Mortensen NJ and Bodmer W: Targeted killing of colorectal cancer cell lines by a humanised IgG1 monoclonal antibody that binds to membrane-bound carcinoembryonic antigen. Br J Cancer. 98:1217–1225. 2008. View Article : Google Scholar : PubMed/NCBI
9	Koppe MJ, Bleichrodt RP, Soede AC, Verhofstad AA, Goldenberg DM, Oyen WJ and Boerman OC: Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin. J Nucl Med. 45:1224–1232. 2004.PubMed/NCBI
10	Olafsen T and Wu AM: Antibody vectors for imaging. Semin Nucl Med. 40:167–181. 2010. View Article : Google Scholar : PubMed/NCBI
11	Chakravarty R, Goel S and Cai W: Nanobody: The ‘magic bullet’ for molecular imaging? Theranostics. 4:386–398. 2014. View Article : Google Scholar : PubMed/NCBI
12	Siontorou CG: Nanobodies as novel agents for disease diagnosis and therapy. Int J Nanomedicine. 8:4215–4227. 2013. View Article : Google Scholar : PubMed/NCBI
13	Desmyter A, Decanniere K, Muyldermans S and Wyns L: Antigen specificity and high affinity binding provided by one single loop of a camel single-domain antibody. J Biol Chem. 276:26285–26290. 2001. View Article : Google Scholar : PubMed/NCBI
14	Cancer of the Lung and Bronchus-SEER Stat Fact Sheets 2016. 2016.
15	Grunnet M and Sorensen JB: Carcinoembryonic antigen (CEA) as tumor marker in lung cancer. Lung Cancer. 76:138–143. 2012. View Article : Google Scholar : PubMed/NCBI
16	Tomita M, Shimizu T, Ayabe T, Yonei A and Onitsuka T: Prognostic significance of tumour marker index based on preoperative CEA and CYFRA 21-1 in non-small cell lung cancer. Anticancer Res. 30:3099–3102. 2010.PubMed/NCBI
17	Ghosh I, Bhattacharjee D, Das AK, Chakrabarti G, Dasgupta A and Dey SK: Diagnostic role of tumour markers CEA, CA15-3, CA19-9 and CA125 in lung cancer. Indian J Clin Biochem. 28:24–29. 2013. View Article : Google Scholar : PubMed/NCBI
18	Dai H, Liu J, Liang L, Ban C, Jiang J, Liu Y, Ye Q and Wang C: Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers. Respirology. 19:707–713. 2014. View Article : Google Scholar : PubMed/NCBI
19	Liu GL, Liu X, Lv XB, Wang XP, Fang XS and Sang Y: miR-148b functions as a tumor suppressor in non-small cell lung cancer by targeting carcinoembryonic antigen (CEA). Int J Clin Exp Med. 7:1990–1999. 2014.PubMed/NCBI
20	Bell A, Wang ZJ, Arbabi-Ghahroudi M, Chang TA, Durocher Y, Trojahn U, Baardsnes J, Jaramillo ML, Li S, Baral TN, et al: Differential tumor-targeting abilities of three single-domain antibody formats. Cancer Lett. 289:81–90. 2010. View Article : Google Scholar : PubMed/NCBI
21	Wu W, Li S, Zhang W, Sun J, Ren G and Dong Q: A novel VHH antibody targeting the B cell-activating factor for B-cell lymphoma. Int J Mol Sci. 15:9481–9496. 2014. View Article : Google Scholar : PubMed/NCBI
22	Xavier C, Devoogdt N, Hernot S, Vaneycken I, D'Huyvetter M, De Vos J, Massa S, Lahoutte T and Caveliers V: Site-specific labeling of his-tagged Nanobodies with ⁹⁹mTc: A practical guide. Methods Mol Biol. 911:485–490. 2012. View Article : Google Scholar : PubMed/NCBI
23	Gainkam LO, Huang L, Caveliers V, Keyaerts M, Hernot S, Vaneycken I, Vanhove C, Revets H, De Baetselier P and Lahoutte T: Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. J Nucl Med. 49:788–795. 2008. View Article : Google Scholar : PubMed/NCBI
24	Aerts A, Impens NR, Gijs M, D'Huyvetter M, Vanmarcke H, Ponsard B, Lahoutte T, Luxen A and Baatout S: Biological carrier molecules of radiopharmaceuticals for molecular cancer imaging and targeted cancer therapy. Curr Pharm Des. 20:5218–5244. 2014. View Article : Google Scholar : PubMed/NCBI
25	Teng FF, Meng X, Sun XD and Yu JM: New strategy for monitoring targeted therapy: Molecular imaging. Int J Nanomedicine. 8:3703–3713. 2013.PubMed/NCBI